Get Support

Search global stocks & ETFs...Ctrl K

Learn Mode

UTHR - United Therapeutics Corp

197

$566.99

-$1.59 (-0.280%)

At market close

$567.00

$0.005 (0.001%)

After Hours 5/18/26, 9:00 PM

3.74/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

UTHR

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$23.98B

Industry

Biotechnology

EPS (TTM)

$27.27

P/E (TTM)

18.63

Div & Yield

--

FCF Payout Ratio

--

P/S (TTM)

7.57

P/B

4.06

Diluted Shares

47.20M

Ex-Dividend

--

Next Earnings

07-28

Forward P/E

19.26

Payout Ratio

--

P/FCF (TTM)

23.71

FCF Yield

4.22%

Earnings Yield

5.37%

52 Week Range

Score Card

Explore Scores Tab

3.74

Good

United Therapeutics Corp has grown revenue at 5.87% over the past year, which suggests sales are increasing. Also, it has more cash than liabilities meaning it could use its current cash position to be completely debt-free, if it wanted to.

Valuation Model

Key Score

3.00

Average

Management

5.00

Very Good

Growth

5.00

Very Good

Profitability

5.00

Very Good

Fin. Health

3.00

Average

Dividends

--

--

Analyst

1.00

Very Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

10 new filings were in the last 7 days

Filter Form Types

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-18 18:18:12

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-15 17:04:41

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-15 17:04:04

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-14 17:54:55

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-14 17:54:25

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-13 16:31:54

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-13 16:31:08

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-12 17:25:46

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-12 17:25:06

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-05-12 17:16:08

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-11 16:30:32

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-11 07:37:39

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-05-11

High:

$787.50

38.9%

Avg:

$670.72

18.3%

Low:

$521.16

-8.1%

(% change is relative to the current stock price: $566.99)

Analyst Recommendations

Go to Analyst Tab

4.09

Good

32%

Strong Buy (7)

45%

Buy (10)

23%

Hold (5)

0%

Sell (0)

0%

Strong Sell (0)

About

Website
https://www.unither.com/
Address
1000 Spring St, Silver Spring MARYLAND, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1082554

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. The company is headquartered in Silver Spring, Maryland and currently employs 1,400 full-time employees. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.

IPO Date

1999-06-17

Industry

Biotechnology

Total Employees

1,400

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences